PhaseBio Pharmaceuticals Non-operating Interest Expenses

Non-operating Interest Expenses of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending June 29, 2021 was $5 Thousand (a 150.0% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses increased by 66.67%
  • Annual Non-operating Interest Expenses for 2020 was $237 Thousand (a -85.02% decrease from previous year)
  • Annual Non-operating Interest Expenses for 2019 was $1.58 Million (a 308.79% increase from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $387 Thousand (a 644.23% increase from previous year)
  • Twelve month Non-operating Interest Expenses ending June 29, 2021 was $12 Thousand (a -57.14% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses decreased by -98.44% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$12 Thousand $28 Thousand $404 Thousand $767 Thousand
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of PhaseBio Pharmaceuticals

Most recent Non-operating Interest Expensesof PHAS including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.01 $0.0
2020 $0.0 $0.0 $0.02 $0.38 $0.24
2019 $0.37 $0.27 $0.22 $0.23 $1.58
2018 $0.18 $0.89 $1.45 $1.4 $0.39
2017 $0.62 $0.05
2016 $0.03

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.